Talphera (NASDAQ:TLPH) Posts Quarterly Earnings Results

by · The Cerbat Gem

Talphera (NASDAQ:TLPH – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03, Zacks reports.

Here are the key takeaways from Talphera’s conference call:

  • Talphera said the NEPHRO CRRT study is progressing well, with enrollment now well above the 50% milestone and the company still expecting to complete enrollment in 2026.
  • Management reiterated plans to file the PMA in 2026 and still targets a potential Niyad approval in 2027, saying the company is positioned for that timeline.
  • The company said it does not plan additional enrollment updates before study completion; it expects to announce last patient out, then release top-line data within about a month afterward.
  • Talphera ended the quarter with $21.1 million in cash and said that, along with future conditional tranches, should fund operations through at least a potential PMA approval next year.
  • Cash operating expenses rose to $3.9 million from $2.9 million a year ago, driven mainly by higher Niyad development spending and some increased G&A costs.

Talphera Trading Up 5.1%

Shares of NASDAQ:TLPH traded up $0.04 during trading on Wednesday, reaching $0.90. The company’s stock had a trading volume of 142,385 shares, compared to its average volume of 218,790. The stock has a market capitalization of $46.78 million, a PE ratio of -2.44 and a beta of 0.79. Talphera has a 12 month low of $0.38 and a 12 month high of $1.57. The firm’s 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $1.00.

Insider Buying and Selling

In related news, insider Badri N. Dasu acquired 35,000 shares of the stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of $0.81 per share, with a total value of $28,350.00. Following the purchase, the insider directly owned 76,230 shares of the company’s stock, valued at approximately $61,746.30. This trade represents a 84.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Shakil Aslam bought 35,000 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the acquisition, the insider owned 83,178 shares in the company, valued at approximately $67,374.18. This trade represents a 72.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 433,674 shares of company stock valued at $304,348. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TLPH. Group One Trading LLC lifted its holdings in shares of Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the last quarter. Virtu Financial LLC purchased a new stake in Talphera in the 3rd quarter worth about $29,000. Mariner LLC lifted its stake in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Talphera during the fourth quarter valued at approximately $42,000. Finally, Dauntless Investment Group LLC purchased a new position in shares of Talphera during the third quarter valued at approximately $89,000. 37.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on TLPH. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research note on Monday, April 20th. Westpark Capital assumed coverage on Talphera in a research note on Thursday, April 30th. They issued a “buy” rating and a $3.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

Read Our Latest Stock Analysis on TLPH

About Talphera

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.

Featured Articles